BioCentury | Jan 23, 2021
Translation in Brief

Ionis’ ASO therapy for MM; plus epigenetic modification prevents myeloma-associated bone loss and bryostatin analogs reduce neuroinflammation

Ionis’ antisense oligonucleotide therapy prevents malignant myeloma regenerationUniversity of California San Diego and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) researchers described in Cell Stem Cell an IRF4 antisense oligonucleotide (ASO), ION251, that reduced tumor growth, impaired myeloma progenitor regeneration and...
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...
BioCentury | Jan 21, 2021
Product Development

Merck KGaA’s bintrafusp alfa miss suggests there’s still more to learn about TGFβ

The Phase III miss for Merck KGaA’s bintrafusp alfa in non-small cell lung cancer takes one of the most promising indications for the GSK-partnered program out of contention, and raises questions about...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

The debut of two more venture-backed companies developing early cancer detection tests suggests there is still appetite for new approaches, even as bigger players consolidate via M&A and prepare for commercial launch. Delfi Diagnostics Inc....
BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

After two decades at Alkermes plc (NASDAQ:ALKS), James Frates will join neurodegenerative diseases company Amylyx Pharmaceuticals Inc. as CFO on Jan. 25. Frates said he felt a “calling” to do more to combat amyotrophic lateral sclerosis after his cousin...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

Paige’s $100 million series C suggests investor enthusiasm for cancer diagnostics extends beyond liquid biopsy and includes machine-learning tools for image-based pathology.  The New York-based company will use the funds to speed development of clinical applications,...
BioCentury | Jan 13, 2021
Product Development

Why Verve chose base editing over standard CRISPR for its lead CV candidate

Verve’s non-human primate data makes the case that base editing can produce durable and efficient changes in protein production by the liver, with a clear route to protection from heart attack. Six-month data shared by...
BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...
BioCentury | Jan 8, 2021
Product Development

Caplan sees a host of bioethical turning points coming out of the pandemic

The reckoning that will come after the pandemic will see broad if not tectonic shifts in drug development, from clinical trial conduct to scientific publishing, according to bioethicist Arthur Caplan....
BioCentury | Jan 8, 2021
Deals

ArsenalBio reaches next stage of maturity with BMS deal

In its first deal with a major pharma, ArsenalBio will put its synthetic biology toolkit to the test in creating programmable T cell therapies against solid tumor targets chosen by BMS. ArsenalBio as among the...
Items per page:
1 - 10 of 13844